title: EphB1 and Ephrin-B, new potential biomarkers for squamous cell/adenosquamous carcinomas and adenocarcinomas of the gallbladder.
abstract: Squamous cell/adenosquamous carcinoma (SC/ASC) of the gallbladder are rare tumors and there are few clinical reports in the literature. Herein we report our clinical experience with 46 patients with SC/ASC and 80 with adenocarcinoma (AC). Expression of EphB1 and Ephrin-B in each tumor was determined using immunohistochemical methods for determination of correlations with prognosis. There was no difference in EphB1 and Ephrin-B expression between SC/ASC and AC tumors (P>0.05), but greater expression in those less than 3 cm in diameter, stage I or II (TNM stage), with no lymph node metastases, with no local invasion and treated with radical resection was apparent. Expression of EphB1 (P<0.05) and Ephrin-B (P<0.01) was higher in well differentiated than in poorly differentiated AC tumors. Kaplan-Meier survival analysis indicated that degree of differentiation, tumor diameter, lymph node metastases, local invasion, surgical approach and expression rate of EphB1 and Ephrin-B were closely related to the survival of SC/ASC (P<0.05) and AC patients (P<0.01). Patients with tumors that positive expressed EphB1 and Ephrin-B, whether it is SC/ASC (P SC/ASC =0.000) or AC (P AC =0.000 or P AC =0.002) had longer survival than those negative expression. Cox multivariate analysis indicated a negative correlation between expression of EphB1 or Ephrin-B and overall survival. Hence, EphB1 and Ephrin-B could be regarded as independent good prognostic factorsand important biological markers for SC/ASC and AC of gallbladder.
authors.affiliation: Department of Pathology, Third Xiangya Hospital, Central South University, Changsha, China E-mail : yangzhulin8@sina.com.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Yuan
authors.forename: Zhu-Lin
authors.initials: ZL
authors.lastname: Yang
authors.forename: Xiong-Ying
authors.initials: XY
authors.lastname: Miao
authors.forename: Zi-Ru
authors.initials: ZR
authors.lastname: Liu
authors.forename: Dai-Qiang
authors.initials: DQ
authors.lastname: Li
authors.forename: Qiong
authors.initials: Q
authors.lastname: Zou
authors.forename: Jing-He
authors.initials: JH
authors.lastname: Li
authors.forename: Lu-Feng
authors.initials: LF
authors.lastname: Liang
authors.forename: Gui-Xiang
authors.initials: GX
authors.lastname: Zeng
authors.forename: Sen-Lin
authors.initials: SL
authors.lastname: Chen
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D018196:Carcinoma, Adenosquamous / Q000175:diagnosis / Q000401:mortality / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000401:mortality / Q000473:pathology; D036387:Ephrin-B1 / Q000096:biosynthesis*; D005260:Female; D005704:Gallbladder / Q000473:pathology; D005706:Gallbladder Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D036225:Receptor, EphB1 / Q000096:biosynthesis*
chemical_list: D014408:Biomarkers, Tumor; C484288:EFNB1 protein, human; D036387:Ephrin-B1; D036225:Receptor, EphB1